MDGL

546.89

3.22% 17.05

Dopo l'orario di chiusura: 545.24 -1.65 -0.30%

Madrigal Pharmaceuticals Inc (MDGL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché MDGL Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$529.84

Aprire:

$531.19

Volume 24 ore:

344.93K

Relative Volume:

0.94

Capitalizzazione di mercato:

$12.55B

Reddito:

$958.40M

Utile/perdita netta:

$-288.28M

Rapporto P/E:

-42.51

EPS:

-12.8641

Flusso di cassa netto:

$-193.02M

1 W Prestazione:

+5.42%

1M Prestazione:

+25.54%

6M Prestazione:

+21.63%

1 anno Prestazione:

+63.45%

Intervallo 1D:

$522.49

$547.98

Intervallo di 1 settimana:

$498.03

$547.98

Portata 52W:

$265.00

$615.00

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Nome

Madrigal Pharmaceuticals Inc

Settore

Healthcare (1118)

Industria

Biotechnology (624)

Telefono

404-380-9263

Indirizzo

200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA

Dipendente

915

Cinguettio

@MadrigalPharma

Prossima data di guadagno

2024-10-31

Ultimi documenti SEC

MDGL's Discussions on Twitter

Compare MDGL vs VRTX, REGN, ARGX, ALNY, INSM

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
MDGL Madrigal Pharmaceuticals Inc	546.89	12.55B	958.40M	-288.28M	-193.02M	-12.86
VRTX Vertex Pharmaceuticals Inc	438.71	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	761.85	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	746.42	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	318.85	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	162.43	35.01B	606.42M	-1.28B	-997.58M	-6.403

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-28	Iniziato	Barclays	Overweight
2026-01-06	Downgrade	Wolfe Research	Outperform → Peer Perform
2025-11-05	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2025-11-03	Aggiornamento	BofA Securities	Underperform → Neutral
2025-10-15	Iniziato	Truist	Buy
2025-09-04	Ripresa	H.C. Wainwright	Buy
2025-02-28	Aggiornamento	B. Riley Securities	Neutral → Buy
2025-02-27	Reiterato	H.C. Wainwright	Buy
2024-06-28	Iniziato	Cantor Fitzgerald	Neutral
2024-06-11	Iniziato	Wolfe Research	Outperform
2024-04-22	Iniziato	BofA Securities	Underperform
2024-03-15	Aggiornamento	B. Riley Securities	Sell → Neutral
2024-03-06	Iniziato	Citigroup	Buy
2024-02-26	Downgrade	B. Riley Securities	Neutral → Sell
2022-12-20	Reiterato	Oppenheimer	Outperform
2022-12-19	Reiterato	H.C. Wainwright	Buy
2022-12-19	Reiterato	Piper Sandler	Overweight
2022-12-19	Aggiornamento	Raymond James	Underperform → Mkt Perform
2022-07-08	Downgrade	B. Riley Securities	Buy → Neutral
2021-10-07	Iniziato	Jefferies	Buy
2021-08-06	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2021-05-20	Ripresa	Goldman	Buy
2020-11-24	Ripresa	Evercore ISI	Outperform
2020-11-06	Reiterato	H.C. Wainwright	Buy
2020-07-31	Iniziato	Piper Sandler	Overweight
2020-06-05	Iniziato	BMO Capital Markets	Market Perform
2020-05-05	Iniziato	Chardan Capital Markets	Buy
2020-01-30	Iniziato	Canaccord Genuity	Buy
2020-01-09	Aggiornamento	UBS	Neutral → Buy
2019-11-07	Reiterato	H.C. Wainwright	Buy
2019-06-25	Iniziato	Stifel	Hold
2019-06-10	Aggiornamento	B. Riley FBR	Neutral → Buy
2019-02-28	Reiterato	H.C. Wainwright	Buy
2019-02-22	Iniziato	SVB Leerink	Outperform
2019-01-23	Iniziato	UBS	Neutral
2018-12-14	Iniziato	Wolfe Research	Outperform
2018-12-12	Iniziato	B. Riley FBR	Neutral
2018-11-19	Downgrade	Raymond James	Mkt Perform → Underperform
2018-11-16	Aggiornamento	Evercore ISI	In-line → Outperform
2018-09-04	Iniziato	Citigroup	Buy
2018-08-06	Downgrade	Goldman	Buy → Neutral
2018-06-28	Iniziato	Raymond James	Mkt Perform

Mostra tutto

Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie

Apr 04, 2026

MDGL Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai

Apr 04, 2026

Toth Financial Advisory Corp Makes New $1.17 Million Investment in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Apr 04, 2026

Madrigal Pharmaceuticals Grants Equity Awards to New Employees Under 2025 Inducement Plan - MSN

Apr 04, 2026

Apr 03, 2026

MDGL stock surges most in a month on Eli Lilly buyout speculation - MSN

Apr 03, 2026

What makes Madrigal Pharma (MDGL) one of the shorted biotech stocks to buy - MSN

Apr 03, 2026

Apr 02, 2026

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Apr 02, 2026

Apr 01, 2026

Madrigal Pharmaceuticals to Present at Morgan Stanley Global Health Care Conference - MSN

Apr 01, 2026

Madrigal grants equity awards to seven new employees - MSN

Apr 01, 2026

Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $964 - Moomoo

Apr 01, 2026

Mar 31, 2026

The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step - Benzinga

Mar 31, 2026

Why Madrigal Pharmaceuticals (MDGL) Is Up 14.1% After Expanding Its MASH Franchise Beyond Rezdiffra - Sahm

Mar 31, 2026

Madrigal Soars 5.87% on Strong Analyst Momentum and Institutional Shifts—Where to Now? - bitget.com

Mar 31, 2026

Hennion & Walsh Asset Management Inc. Sells 4,684 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Mar 31, 2026

MDGL Technical Analysis | Trend, Signals & Chart Patterns | MADRIGAL PHARMACEUTICALS INC (NASDAQ:MDGL) - ChartMill

Mar 31, 2026

Understanding Momentum Shifts in (MDGL) - Stock Traders Daily

Mar 31, 2026

Mar 30, 2026

Madrigal Pharmaceuticals grants equity awards to 20 new employees - MSN

Mar 30, 2026

Madrigal Pharmaceuticals (MDGL) surged on strong sales of its Rezdiffra drug - MSN

Mar 30, 2026

Assenagon Asset Management S.A. Acquires New Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Mar 30, 2026

Mar 29, 2026

Madrigal Pharmaceuticals stock dips after team presence at Liver Connect Conference sees doubled attendance - Traders Union

Mar 29, 2026

Mar 27, 2026

Madrigal Reports $212.8M in Q2 Rezdiffra Sales, Expands Global Pipeline and Secures $500M Financing - MSN

Mar 27, 2026

Loss Report: What are analysts price targets for Madrigal Pharmaceuticals Inc2026 Bull vs Bear & Technical Pattern Based Signals - baoquankhu1.vn

Mar 27, 2026

MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation - Stocktwits

Mar 27, 2026

Madrigal Pharmaceuticals (MDGL) Surged on Strong Sales of Its Rezdiffra Drug - Insider Monkey

Mar 27, 2026

Vanguard (MDGL) files amendment; reports 0 shares after Jan 12, 2026 realignment - Stock Titan

Mar 27, 2026

Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains? - Yahoo Finance

Mar 27, 2026

Is It Too Late To Consider Madrigal Pharmaceuticals (MDGL) After Recent Share Price Surge? - Yahoo Finance

Mar 27, 2026

Mar 26, 2026

Madrigal Pharmaceuticals gains amid renewed takeover speculation - MSN

Mar 26, 2026

Rezdiffra Shows Promise as Madrigal’s Liver Drug Garners Positive Results - StocksToTrade

Mar 26, 2026

Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading 11.7% HigherShould You Buy? - marketbeat.com

Mar 26, 2026

Madrigal Surges 11.66%: A Volatile Breakout Defies Sector Stagnation as Bulls Test $572 - Bitget

Mar 26, 2026

Madrigal Grants Equity Awards to Seven New Employees - MyChesCo

Mar 26, 2026